Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428794 | 1.00 | CTRB1 (0.54) | CTRB1SYKATMALDH1A1TRPM8 | |
| SCHEMBL25851914 | 0.91 | CTRB1 (0.51) | CTRB1SYKATMALDH1A1TRPM8 | |
| SCHEMBL116393 | 0.88 | CTRB1 (0.56) | CTRB1SYKATMALDH1A1ALOX15 | |
| SCHEMBL1605999 | 0.88 | CTRB1 (0.58) | CTRB1SYKATMCTSKCASP1 | |
| SCHEMBL1606000 | 0.88 | CTRB1 (0.58) | CTRB1SYKATMCTSKCASP1 | |
| SCHEMBL5198016 | 0.88 | CTRB1 (0.58) | CTRB1SYKATMCTSKCASP1 | |
| SCHEMBL143120 | 0.88 | SYK (0.60) | CTRB1SYKATMCTSKCASP1 | |
| SCHEMBL1556449 | 0.88 | SYK (0.60) | CTRB1SYKATMCTSKCASP1 | |
| SCHEMBL555191 | 0.86 | CTRB1 (0.57) | CTRB1SYKATMALDH1A1TRPM8 | |
| SCHEMBL79250 | 0.86 | CTRB1 (0.57) | CTRB1SYKATMALDH1A1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924307-B2 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| EP-1167346-A1 | 4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | GABBR1, GABRB1, GABBR2 | CTRB1 776/4885SYK 4039/4885ATM 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.